Ospemifene metabolism in humans in vitro and in vivo: Metabolite identification, quantitation, and CYP assignment of major hydroxylations

Drug Metabolism and Drug Interactions

Volumn 28, Issue 3, 2013, Pages 153-161

  Tolonen, Ari ^a,b   Koskimies, Pasi ^c   Turpeinen, Miia ^d   Uusitalo, Jouko ^a,e   Lammintausta, Risto ^c   Pelkonen, Olavi ^d  

^a Novamass Analytical Ltd   (Finland)

^b Admescope Ltd   (Finland)

^c Hormos Medical Ltd   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e Technopolis Oyj   (Finland)

Author keywords

CYP assignment; Human liver preparations; Metabolite profile in vitro and in vivo; Ospemifene; Selective CYP inhibitors

Indexed keywords

4 HYDROXY OSPEMIFENE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONIDE; OSPEMIFENE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; DRUG DETERMINATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; LIVER MICROSOME;

CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; HYDROXYLATION; LIVER; MICROSOMES, LIVER; RECOMBINANT PROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84888113175     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2013-0016     Document Type: Article

References (10)

1. Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17: 480-6.
2. Simon JA. Efficacy and safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. In: North American Menopause Society, Orlando, FL, USA, October 3-6, 2012.
3. Komi J, Lankinen KS, Härkönen P, DeGregorio MW, Voipio S, Kivinen S, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12: 202-9. (Pubitemid 40464289)
4. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 2005;96: 167-75. (Pubitemid 40387992)
5. Unkila M, Kari S, Yatkin E, Lammintausta R. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol, accepted for publication.
6. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, Pasanen M. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 2007;37: 1367-77. (Pubitemid 350146687)
7. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138: 103-41.
8. Pelkonen O, Kaltiala EH, Larmi TK, Karki NT. Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. Chem Biol Interact 1974;9: 205-16.
9. Bradford MM. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-54.
10. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6: 140-8. (Pubitemid 46745341)